Clinical Trial of the MiniStim PNS for Knee Pain- "FLEX" Study

Not Applicable

Recruiting

• Conditions: Chronic Knee Pain
• Interventions: Device: MiniStim PNS

• Registration Number: NCT04580732
• Lead Sponsor: MiniStim LLC

Brief Summary

This is a prospective, multi-center, randomized, study in which 300 evaluable subjects will be randomized 1:1 to receive active or delayed therapy with Moments PNS. Subjects in the Delayed group will start with therapy at 3-month visit follow up. The primary endpoint is a \>50% pain relief at 3-months as measured by the Visual Analog Scale (VAS) without increase in baseline pain medications, with additional measurements assessed at 3, 6, 9, 12, 24, and 36-months.

Detailed Description

This is a prospective, randomized, controlled, multi-center study in which up to 300 evaluable subjects will receive MiniStim PNS. Target subjects will have chronic knee pain.

Subjects will be randomized into either the active or delayed group. Devices will be activated post-op in accordance to the randomization assignment. Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study. Implanted subjects will be educated on the use of the transmitter. Programming changes can be done as needed during this time period to maximize clinical response according to pre-programmed settings. Subjects randomized to the Delayed group will begin 2-hour stimulation/day at the 3-Month visit.

The primary endpoint will be at 3-Months, comparing Active vs. Delayed data from baseline data, and subjects in the Delay group will begin stimulation. At the 3-month visit, VAS will be completed and compared to baseline VAS, during this visit the safety and efficacy of the device will be assessed, and subjects in the Delayed group will be instructed to begin daily stimulation for a minimum of 2 hours a day. Subjects will be seen at 3-month intervals through the 12-Month visit for data collection and adverse event review. Subjects will continue therapy and followed for a total of 36-months with primary outcomes assessed at 3-months. Their participation in the study will end at 36-months.

Study Timeline

• Study First Submitted: 2020-09-28
• Study First Submitted QC: 2020-10-02
• Study First Posted: 2020-10-08
• Study Start: 2021-05-05
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-03
• Last Update Posted: 2023-10-06
• Primary Completion: 2024-12
• Study Completion: 2025-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

A. Capable of giving informed consent and willing to follow all study related procedures;

B. Women and men >18 years of age;

C. Baseline VAS score of > 5;

D. History of chronic, function-limiting knee pain of at least three months;

E. Not had recent surgical procedures of the knee within the last three months;

F. ≥50% temporary relief from temporary nerve diagnostics;

G. No evidence of anatomic abnormalities that could jeopardize the placement of the device;

H. Able to operate programmer, recharger, study assessments and provide accurate responses;

I. Appropriate candidate for the implant procedure based on the opinion of investigator.

Exclusion Criteria

A. An active implantable electronic device regardless of whether stimulation is ON or OFF;

B. Dependency on utilizing wearable or transcutaneous monitoring device (hearing aids, continuous glucose monitors, etc.);

C. Pregnant as confirmed by a urine pregnancy test or plan to become pregnant during study;

D. Subject noted no relief from temporary nerve diagnostics;

E. Inability to achieve appropriate positioning;

F. Inability to understand informed consent and protocol;

G. Conditions requiring recurring MRI evaluation or diathermy procedures;

H. Anatomical restrictions such that device placement is not possible;

I. Have a life expectancy of less than 1-year;

J. Worker's compensation claimants;

K. Based on opinion of investigator any legal concerns that would preclude his/her enrollment in the study or potentially confound results;

L. Deemed unsuitable for enrollment by investigator based on medical history or physical examination.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Delayed	MiniStim PNS	The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
Active	MiniStim PNS	Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.

Primary Outcome Measures

Name	Time	Method
Rate of Change in Pain Relief: >50% pain relief as measured by Visual Analog Scale	3-Months	Improvement pain defined as a \>50% pain relief as measured by VAS without increase in baseline medications. To demonstrate clinically significant improvements in the pain of subjects in the active group compared to the subjects in the delayed group.
Adverse Events	3-months	Device- and procedure-related Adverse Events (AE) rate at 3-months.

Secondary Outcome Measures

Name	Time	Method
Change in Range of Motion	3, 6, 9, 12, 24, 36-months	Change in knee range of motion as measured with Knee Range of Motion questionnaire.
Physical Function: Ability to do one-legged knee bends	3, 6, 9, 12, 24, 36-months	The ability to do one-legged knee bends (percentage increase in knee bends).
Subset Symptoms: Mental Component Score	3, 6, 9, 12, 24, 36-months	Change in Mental Component Score measured by SF-36 questionnaire measured on a scale of 1-5; 1 (all of the time) to 5 (none of the time).
Subset Symptoms: Physical Component Score	3, 6, 9, 12, 24, 36-months	Change in Physical Component Score measured by SF-36 questionnaire measured on a scale of 1-5; 1 (all of the time) to 5 (none of the time).
Medication Usage	3, 6, 9, 12, 24, 36-months	Medication usage before and after treatment in active and delayed group subjects.

Trial Locations

Locations (1)

Seva Medical; 🇺🇸 Lewisville, Texas, United States